Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
February 28 2024 - 7:00AM
Business Wire
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome
therapeutics company, today announced that management will host a
conference call and live audio webcast on March 5, 2024 at 8:30
a.m. ET to discuss fourth quarter and full year 2023 results and
provide a general business update.
To access the conference call, please dial 800-715-9871
(domestic) or 646-307-1963 (international) and reference the
conference ID number 4030622. To join the live webcast, please
visit the “Investor and News” section of the Seres website at
www.serestherapeutics.com.
A webcast replay will be available on the Seres website
beginning approximately two hours after the event and will be
archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage
company developing novel microbiome therapeutics for serious
diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval
in April 2023 as the first orally administered microbiome
therapeutic to prevent recurrence of C. difficile infection (CDI)
in adults following antibacterial treatment for recurrent CDI and
is being commercialized in collaboration with Nestlé Health
Science. Seres is evaluating SER-155 in a Phase 1b study in
patients receiving allogeneic hematopoietic stem cell
transplantation. For more information, please visit
www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228634673/en/
Investor and Media: Rob Windsor
Rwindsor@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2024 to May 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From May 2023 to May 2024